The mission of GAIA Vaccine Foundation is Global Vaccine, Global Access. It is the goal of GAIA to distribute the HIV vaccine developed as a result of this project at no profit in developing countries. Initial studies of the GAIA HIV/AIDS vaccine are being carried out by Dr. Annie De Groot and Bill Martin at EpiVax, a Rhode Island based bioinformatics company, in collaboration with Dr. Ken Mayer at the Miriam Hospital and Dr. Ousmane Koita of the Faculty of Science and Technology at the University of Bamako. These three entities, working in collaboration, and depending on funding, project that they will deliver a vaccine ready for a Phase I clinical trials within four years.